Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review

September 2021 | 51 pages | ID: I0DB73E697BEN
GlobalData

Abstracts

Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmuPharma Plc (ImmuPharma) biopharmaceutical company that focuses on discovery and development of peptide-based therapeutics for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection. The company’s product pipeline comprises Lupuzor, for the treatment of Lupus; IIP

203101, for treatment of methicillin-resistant Staphylococcus aureus; BioGlucagon for treatment of diabetes and IPP-204106, for the treatment of cancer; and peptide platform for the treatment of metabolic disorders. It has operations in France and Switzerland. ImmuPharma is headquartered in London, Greater London, the UK.

Immupharma Plc Key Recent Developments

Jul 30,2021: ImmuPharma: Board changes
Jul 16,2021: ImmuPharma: Board Appointment
May 24,2021: Immupharma: Director retirement
Apr 29,2021: Immupharma announce Final Results
Apr 29,2021: ImmuPharma: Final results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Immupharma Plc - Key Facts
Immupharma Plc - Key Employees
Immupharma Plc - Key Employee Biographies
Immupharma Plc - Major Products and Services
Immupharma Plc - History
Immupharma Plc - Company Statement
Immupharma Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Immupharma Plc - Business Description
Immupharma Plc - Corporate Strategy
Immupharma Plc - SWOT Analysis
SWOT Analysis - Overview
Immupharma Plc - Strengths
Immupharma Plc - Weaknesses
Immupharma Plc - Opportunities
Immupharma Plc - Threats
Immupharma Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Immupharma Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 30, 2021: ImmuPharma: Board changes
Jul 16, 2021: ImmuPharma: Board Appointment
May 24, 2021: Imm harma: Director retirement
Apr 29, 2021: ImmuPharma: Final results
Apr 29, 2021: Imm harma announce Final Results
Sep 30, 2020: ImmuPharma : Interim results announcement for the six months ended 30 June 2020
Apr 30, 2020: ImmuPharma : Final results announcement for the twelve months ended 31 December 2019

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Immupharma Plc, Key Facts
Immupharma Plc, Key Employees
Immupharma Plc, Key Employee Biographies
Immupharma Plc, Major Products and Services
Immupharma Plc, History
Immupharma Plc, Subsidiaries
Immupharma Plc, Key Competitors
Immupharma Plc, Ratios based on current share price
Immupharma Plc, Annual Ratios
Immupharma Plc, Annual Ratios (Cont...1)
Immupharma Plc, Interim Ratios
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Immupharma Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Immupharma Plc, Performance Chart (2016 - 2020)
Immupharma Plc, Ratio Charts
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Immupharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021